Abstract
Cardiovascular disease (CVD) remains the leading cause of premature death in patients with chronic kidney disease (CKD). Recent evidence suggests that the interaction of ‘‘classic’’ and ‘‘non-classic” cardiovascular risk factors is an important contributor in excessive and accelerated CVD in patients with CKD. Indeed, the imposing cardiovascular morbidity and mortality of CKD patients corresponds to a significant extent in endothelial dysfunction, inflammation, oxidative stress, vascular calcification and volume overload. In addition, the kidney’s function decline is independently associated with CVD in patients with chronic kidney disease. Currently, there is a growing interest in the role of new biomarkers that are closely correlated with CVD in CKD population. In current review, we summarize the so far acquired knowledge of the most promising biomarkers and we discuss the major clinical correlations of novel risk factors and new biomarkers of CVD in CKD patients, their predictive value for future cardiovascular events and their use in the treatment monitoring of this population.
Keywords: Atherosclerosis, biological markers, cardiovascular risk, chronic kidney disease, endothelial dysfunction, endothelium, hemodialysis, inflammation, renal function, kidney disease
Current Medicinal Chemistry
Title:Biomarkers Determining Cardiovascular Risk in Patients with Kidney Disease
Volume: 19 Issue: 16
Author(s): G. Siasos, D. Tousoulis, S. Michalea, E. Oikonomou, C. Kolia, S. Kioufis, A. Synetos, K. Vlasis, A. G. Papavassiliou and C. Stefanadis
Affiliation:
Keywords: Atherosclerosis, biological markers, cardiovascular risk, chronic kidney disease, endothelial dysfunction, endothelium, hemodialysis, inflammation, renal function, kidney disease
Abstract: Cardiovascular disease (CVD) remains the leading cause of premature death in patients with chronic kidney disease (CKD). Recent evidence suggests that the interaction of ‘‘classic’’ and ‘‘non-classic” cardiovascular risk factors is an important contributor in excessive and accelerated CVD in patients with CKD. Indeed, the imposing cardiovascular morbidity and mortality of CKD patients corresponds to a significant extent in endothelial dysfunction, inflammation, oxidative stress, vascular calcification and volume overload. In addition, the kidney’s function decline is independently associated with CVD in patients with chronic kidney disease. Currently, there is a growing interest in the role of new biomarkers that are closely correlated with CVD in CKD population. In current review, we summarize the so far acquired knowledge of the most promising biomarkers and we discuss the major clinical correlations of novel risk factors and new biomarkers of CVD in CKD patients, their predictive value for future cardiovascular events and their use in the treatment monitoring of this population.
Export Options
About this article
Cite this article as:
Siasos G., Tousoulis D., Michalea S., Oikonomou E., Kolia C., Kioufis S., Synetos A., Vlasis K., G. Papavassiliou A. and Stefanadis C., Biomarkers Determining Cardiovascular Risk in Patients with Kidney Disease, Current Medicinal Chemistry 2012; 19 (16) . https://dx.doi.org/10.2174/092986712800492986
DOI https://dx.doi.org/10.2174/092986712800492986 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Kinetic Measurement Techniques in the Evaluation of Lipid Metabolism
Current Drug Discovery Technologies Metabolic Syndrome: Sex-Related Cardiovascular Risk and Therapeutic Approach
Current Medicinal Chemistry Biological Predictors of Aging and Potential of FTIR to Study Age-related Diseases and Aging Metabolic Fingerprint
Current Metabolomics A Journey into the World of Targeted Therapy: A Review of Gene Therapy, Stem Cell Therapy, and Cell Reprogramming in Cardiovascular Medicine
Recent Patents on Regenerative Medicine Nitric Oxide-Derived Oxidants with a Focus on Peroxynitrite: Molecular Targets,Cellular Responses and Therapeutic Implications
Current Pharmaceutical Design Regular Physical Activity and Vascular Aging
Current Pharmaceutical Design Effects of Biologic Agents and Other Disease-Modifying Antirheumatic Drugs on Cardiovascular Outcomes in Psoriasis and Psoriatic Arthritis: A Systematic Review
Current Pharmaceutical Design Glucose Tolerance: Hypothesis Testing on Malaysian Diabetic Community
Current Diabetes Reviews Investigating Drug-induced Mitochondrial Toxicity: A Biosensor to Increase Drug Safety?
Current Drug Safety Drug Eluting Stents: Friend or Foe? A Review of Cellular Mechanisms Behind the Effects of Paclitaxel and Sirolimus Eluting Stents
Current Drug Metabolism Study of the Interaction Between Graphene Oxide and Surface-confined Biomolecules to Develop New Kind of Biosensors
Current Nanoscience NTproBNP: An Important Biomarker in Cardiac Diseases
Current Topics in Medicinal Chemistry Apolipoprotein E Knockout Models
Current Pharmaceutical Design Recent Advances in Fe-MOF Compositions for Biomedical Applications
Current Medicinal Chemistry Coronary Calcium Risk Score and Cardiovascular Risk
Current Vascular Pharmacology From French Paradox to Cancer Treatment: Anti-cancer Activities and Mechanisms of Resveratrol
Anti-Cancer Agents in Medicinal Chemistry Drugs of Abuse: Epigenetic Mechanisms in Toxicity and Addiction
Current Medicinal Chemistry Super-Resolution Based Enhancement of Cardiac MR Images
Current Medical Imaging Similar Mechanisms Regulated by γ-Secretase are Involved in Both Directions of the Bi-Directional Notch-Delta Signaling Pathway as well as Play a Potential Role in Signaling Events Involving Type 1 Transmembrane Proteins
Current Stem Cell Research & Therapy Future Perspectives in the Pharmacological Treatment of Atrial Fibrillation and Ventricular Arrhythmias in Heart Failure
Current Pharmaceutical Design